Autolus Therapeutics plc (AUTL)
- Globe Newswire
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AUTO1 (obecabtagene autoleucel, obe-cel), the company’s CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / r
- Globe Newswire
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade Cytokine Release Syndrome observed Durability of response in ALL patients continues to support potential for transformational therapy in adult ALL Conference Call to be held on Friday, June 11, 2021 at 8:30 am ET / 1:30 pm BST LONDON, June 11, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL),
- Simply Wall St.
What Is The Ownership Structure Like For Autolus Therapeutics plc (NASDAQ:AUTL)?
If you want to know who really controls Autolus Therapeutics plc ( NASDAQ:AUTL ), then you'll have to look at the...
